Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Mar;9(3):626-32.
doi: 10.2215/CJN.05810513. Epub 2013 Aug 29.

Glomerular diseases: FSGS

Bhadran Bose  1 , Daniel Cattran; Toronto Glomerulonephritis Registry
Affiliations
Review

Glomerular diseases: FSGS

Bhadran Bose et al. Clin J Am Soc Nephrol. 2014 Mar.

Abstract

FSGS is a lesion, not a disease. The separation into primary FSGS (a result of immunologic-mediated injury) versus secondary FSGS (related to a variety of causes) is often difficult. Even when this particular issue is carefully evaluated, the therapeutic implications are not always apparent. Newer literature on both biomarker discovery and on the genetic basis of FSGS is reviewed in this context. In addition, the thorny implications of obesity as it relates to the FSGS lesion are discussed. An overall practical algorithmic approach to the management and treatment of the FSGS lesion that integrates these controversial overlap areas is suggested.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overlap of different causal categories of FSGS. There is a complex interaction between different causes of FSGS. The overlap area conceptually indicates patients who may respond to treatment within the overlapping areas of primary and secondary causations.
Figure 2.
Figure 2.
Treatment algorithm for FSGS. *CNI dose as per the KDIGO guidelines on GN. **See the text on options to consider in the management of nonresponders. ***See the text on how to manage relapse. RAS, renin-angiotensin system; CNI, calcineurin inhibitor; MMF, mycophenolate mofetil.
See this image and copyright information in PMC

References

    1. Haas M, Meehan SM, Karrison TG, Spargo BH: Changing etiologies of unexplained adult nephrotic syndrome: A comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 30: 621–631, 1997 - PubMed
    1. Fuchshuber A, Gribouval O, Ronner V, Kroiss S, Karle S, Brandis M, Hildebrandt F: Clinical and genetic evaluation of familial steroid-responsive nephrotic syndrome in childhood. J Am Soc Nephrol 12: 374–378, 2001 - PubMed
    1. Hinkes B, Wiggins RC, Gbadegesin R, Vlangos CN, Seelow D, Nürnberg G, Garg P, Verma R, Chaib H, Hoskins BE, Ashraf S, Becker C, Hennies HC, Goyal M, Wharram BL, Schachter AD, Mudumana S, Drummond I, Kerjaschki D, Waldherr R, Dietrich A, Ozaltin F, Bakkaloglu A, Cleper R, Basel-Vanagaite L, Pohl M, Griebel M, Tsygin AN, Soylu A, Müller D, Sorli CS, Bunney TD, Katan M, Liu J, Attanasio M, O’toole JF, Hasselbacher K, Mucha B, Otto EA, Airik R, Kispert A, Kelley GG, Smrcka AV, Gudermann T, Holzman LB, Nürnberg P, Hildebrandt F: Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet 38: 1397–1405, 2006 - PubMed
    1. Kidney DiseaseImproving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2: 139–274, 2012
    1. Korbet SM: Clinical picture and outcome of primary focal segmental glomerulosclerosis. Nephrol Dial Transplant 14[Suppl 3]: 68–73, 1999 - PubMed

MeSH terms